早期子宫内膜癌患者术后应用黑升麻制剂治疗绝经相关症状

目的 探讨黑升麻制剂(莉芙敏片)用于治疗早期子宫内膜癌患者术后绝经相关症状的安全性和有效性.方法 60例因子宫内膜癌Ⅰ期术后出现绝经相关症状的患者,根据用药意愿分为莉芙敏研究组及不用药对照组,每组各30例.莉芙敏组口服莉芙敏片20 mg,每日2次,共24周;对照组不服药.随访12个月,比较2组的Kupperman绝经指数(KMI)总分、骨密度、肝肾功能、血常规等实验室检查项目及肿瘤复发率、死亡率.结果 莉芙敏组治疗前KMI总分为26±7,治疗24周后为9±4,较治疗前明显降低(P＜0.05);对照组KMI总分治疗前、后分别为25±8和21±5,差异无统计学意义.莉芙敏组骨密度值在治疗前、后分别为(0.790±0.17)和(0.891±0.21) g/cm2,差异有统计学意义(P＜0.05);对照组骨密度值治疗前、后分别为(0.808±0.19)和(0.816±0.15) g/cm2,差异无统计学意义.莉芙敏组服药期间无不良事件发生.随访1年对照组有1例肿瘤复发,莉芙敏组和对照组各有1例死亡.结论 黑升麻制剂可用于改善早期子宫内膜癌患者术后的绝经相关症状,且不增加肿瘤的复发率.

Cimicifuga racemosa for treatment of menopausal symptoms in patients with early endometrial cancer after operation

Objective To evaluate the efficacy and safety of black cohosh(cimicifuga racemaosa,Remifemin) for treatment of menopausal symptoms in patients with early endometrial cancer after operation.Methods Sixty patients with early endometrial cancer,who suffered menopausal symptoms after operation,were evenly divided into experimental group and control group.Patients in the experimental group took Remifemin tablet(20 mg) twice a day for 24 weeks.Patients in the control group took no drugs.All the patients were followed up for 12 months.The Kupperman menopause index(KMI),bone mineral density(BMD),cancer recurrence rate,death rate,and hepatic and renal functions were compared between the two groups.Results The KMI score of the experimental group was significantly decreased 24 weeks after treatment with Remifemin(9±4 vs 26±7,P<0.05),and that in the control group was not significantly changed(21±5 vs 25±8,P>0.05).The BMD in the experimental group was significantly increased 24 h after treatment with Remifemin([0.891±0.21] g/cm2 vs [0.790±0.17] g/cm2,P<0.05);and there was no significant difference in the control group([0.816±0.15] g/cm2 vs [0.808±0.19] g/cm2,P>0.05).No adverse effects were observed in the experimental group.During 1-year follow-up,one patient died in the experimental group;one had recurrence and one died in the control group.Conclusion Black cohosh can improve the menopausal symptoms in patients with early endometrial cancer after operation,without increasing the risk of tumor recurrence.